Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
| ▸ | THRA | P10827 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | LSS | P48449 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19722362 | 0.91 | F2 (0.43) | F2THRBTHRAGAAMAPT | |
| SCHEMBL19722193 | 0.87 | ITGB3 (0.39) | THRBITGB3ITGA2B | |
| SCHEMBL19722415 | 0.85 | ITGB3 (0.34) | THRBTHRAITGB3ITGA2BHRH3 | |
| SCHEMBL19721961 | 0.85 | SPHK1 (0.46) | MAPTKMT2AHRH3 | |
| SCHEMBL19722058 | 0.83 | F2 (0.41) | F2THRBTHRAGAAMAPT | |
| SCHEMBL9398371 | 0.83 | F2 (0.54) | F2THRBTHRAGAAMAPT | |
| SCHEMBL4651768 | 0.83 | F2 (0.54) | F2THRBTHRAGAAMAPT | |
| SCHEMBL4651967 | 0.83 | F2 (0.54) | F2THRBTHRAGAAMAPT | |
| SCHEMBL9398375 | 0.83 | F2 (0.54) | F2THRBTHRAGAAMAPT | |
| SCHEMBL10813927 | 0.82 | F2 (0.49) | F2THRBTHRAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214615-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT | JNC CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | JNC CORPORATION (JP) | 2019-08-27 | — | — | US | disclosed |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORPORATION (JP) | 2017-12-28 | — | — | US | disclosed |
| EP-3257839-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2017-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392339-B2 | Polymerizable polar compound, liquid crystal composition, and liquid crystal display element | SP1, HVCN1, CXCR1 | F2 779/4885THRB 4606/4885THRA 4306/4885 |
| US-20170369418-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | SP1, SPIN1, SAV1 | F2 787/4885THRB 4233/4885THRA 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.